The Columbus DispatchGene Therapy, New Drug Fight Rare Disease in Kids – WebMDWebMDTwo innovative new therapies for spinal muscular atrophy (SMA) type 1 have proven highly effective in clinical trials, researchers report.The Most Expensive Drug in the … Continue reading
The Columbus DispatchGene Therapy, New Drug Fight Rare Disease in Kids – WebMDWebMDTwo innovative new therapies for spinal muscular atrophy (SMA) type 1 have proven highly effective in clinical trials, researchers report.The Most Expensive Drug in the … Continue reading
Phys.OrgStem cell laboratory in a bagPhys.OrgUntil now, stem cell aggregates have been generated by using pipette feeder robots (which are expensive to purchase and maintain) or by means of manual pipetting (which is labor- and time-intensive). Manual … Continue reading
News-Medical.net |
Stem Cell Subset Source of All Blood Cells, Basis of Bone Marrow Transplant Success
Genetic Engineering & Biotechnology News A new blood system isn’t created from scratch—just something close to it. A single type of stem cell, a new study demonstrates, can fully repopulate the bone marrow and give rise to all the cell lineages that constitute a complete blood system. Production of nitric oxide crucial for stem cell mobilization and differentiationNews-Medical.net Subset of Stem Cells Identified as Source for All Cells in Blood and Immune SystemsBioscience Technology Scientists discover stem cells behind bone marrow transplants, pointing the way to new cancer treatmentsGears Of Biz |
Medical News Today |
Gene therapy may protect brain from age-related cognitive decline
Medical News Today The study’s findings are significant because they are the first to show that injecting one dose of Klotho-promoting gene therapy into the central nervous system (CNS) of young mice prevented age-related cognitive decline when they reached old age. |
|
AvidBiotics split creates two biotechs in hot areas
BioPharma Dive Last month, following a patient death, the Food and Drug Administration put a clinical hold on two Phase 1 studies of Cellectis’ gene-edited allogeneic CAR–T therapy, UCART123, in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. |
FierceBiotech |
Chasing Biogen, AveXis posts improved gene therapy data
FierceBiotech AveXis has posted an update on the spinal muscular atrophy (SMA) patients treated with its gene therapy. The latest data show an uptick in the proportion of patients able to sit unassisted and talk, fueling AveXis’ hopes of establishing AVXS-101 as a … AveXis to Report Third Quarter 2017 Financial and Operating ResultsNasdaq |